160 / 464
160
SCIENTIFIC PROGRAMME
| Programme and Exhibition Guide
TUESDAY 9 MAY 2017
techniques can be used. The symposium will provide updates on dose-volume effects
for the major organs at risk for head-and-neck cancer, the thoracic region, as well
as on pelvic treatment sites. This enables to explore emerging factors like genetics
and image feature. Furthermore, challenges and pitfalls of model’s validation will be
addressed in the symposium, such as variations of toxicity across fractionation.
Chair: D. Georg (Austria)
Co-chair: P. Peterlin (Slovenia)
09:15 > Developments in head and neck toxicity data, models, and treatment
optimisation
Speaker: A. Van Der Schaaf (The Netherlands)
SP-0577
09:40 > New NTCP data in the thoracic region: probing ‘dark toxicity’
Speaker: J. Deasy (USA)
SP-0578
10:05 > New NTCP data in the pelvic area
Speaker: C. Fiorino (Italy)
SP-0579
SYMPOSIUM
RT is technology driven. How to keep the patient involved?
09:15 - 10:30 | STRAUS 1
Chair: S.C. Frasca (Italy)
Co-chair: N. Metz (Austria)
09:15 > Patient education – tools to improve patient positioning
Speaker: H. Hansen (Denmark)
SP-0580
09:40 > PROMs analysis to improve communication and enhance practice
Speaker: A. Lemanska (UK)
SP-0582
10:05 > Public knowledge of RT saves lives: the case for RT awareness
Speaker: E. Naessens (Ireland)
SP-0581
SYMPOSIUM
Hypofractionation in prostate cancer
11:00 - 12:00 | STOLZ 1-2
This session will cover the evolution in dose fractionation for prostate cancer. These
new dose fractionation schemes vary from moderate hypofractionation to extreme
hypofractionation. Moderate hypofractionation has been explored in four recent
large phase 3 trials in low, intermediate and high risk prostate cancer.
With high precision radiotherapy we can move to even larger doses per fraction
eg 5 fractions of 7 to 9 Gy to a moderate total dose. Phase 3 studies are currently
ongoing to compare this extreme hypofractionation with conventional or moderate
hypofractionated schedules.